After a PhD in Molecular Medicine, in 2001 she was enrolled as research leader group and assistant Professor in Human Anatomy at the School of Pharmacy (UPO) and from 2015 she was appointed Associate Professor. Her research interests include the development and evaluation of novel biomaterials and tissue regeneration of bone and cartilage.

For complete biography, see the Key Staff page

For complete biography, see the Key Staff page

She received her degree in Pharmacy in 2011 and her PhD in Pharmaceutical and Food Biotechnologies in 2016 at UPO. At present, she is a post-Doc in Pharmacology at the Department of Pharmaceutical Sciences in Novara. Her main research interest focuses on pharmacogenetics, systematic reviews and meta-analysis.

After a PhD in Environmental Medicine at University of Bari, Italy, in 2012 he received a post-graduate degree in Medical Statistics at the University of Milan, Italy. He was a Post-doctoral fellow at the National Institutes of Health, Bethesda, USA and a Lecturer in Epidemiology, St. George’s, University of London, UK. Currently, he is associate professor of public health (UPO). His main research interests include pharmacoepidemiology, evaluation of public health interventions, with a special interest to interventions aimed to the promotion of healthy aging trough life-style modifications, occupational and environmental epidemiology, statistical methods for epidemiology and public health, systematic reviews and meta-analyses.

After a PhD in Medicinal Chemistry at the University of Turin and an experience as chemistry laboratory technician, she became Assistant Professor of Medicinal Chemistry at the Department of Pharmaceutical Sciences (UPO).  Her research interests include the design and synthesis of novel antitumoral agents, especially in the field of nicotinamide phosphoribosyl transferase, PI3Ks and tubulin.

He obtained his PhD in Science of Bioactive Compounds in 2004 and he was a visiting scientist at Endocannabinoid Research Group – CNR – Pozzuoli (Italy) and at the laboratory of Prof. Clayden – University of Manchester (UK). He is currently Associate Professor of Organic Chemistry at the Department of Pharmaceutical Sciences (UPO). His research interests include the chemistry of natural products and the development of novel synthetic methodologies in the synthesis of natural compounds.

After a PhD in Chemistry of Drugs and a Post-Doc at the University of Turin, she became Assistant Professor at the Department of Drug Science and Technology (University of Turin). At present, she is Associate Professor of Pharmaceutical Technology at the Department of Pharmaceutical Sciences (UPO). Her interests include biocompatible colloidal systems, semi-solid preparations for pharmaceutical and cosmetic use and Italian and European legislation on medicinal and healthy products.

For complete biography, see the Key Staff page

She received her PhD in Medicinal Chemistry at the University of Turin in 2003 and at present she is Assistant Professor at the Department of Pharmaceutical Sciences (UPO), where she is lecturer in lecturer in Pharmaceutical Analysis and Analytical Chemistry. Her research interests include the study of the activity, inhibition and enzyme kinetics via LC-MS, the structure-metabolism relationships of drugs via LC-MS, the development of quali/quantitative analytical methods for the characterization of complex mixtures and/or the metabolic products of drugs via LC-UV and LC-MS,  the characterization and determination via LC-MS of the degradation products of molecules of pharmaceutical interest, and the development and validation of analytical methods used in ongoing studies of stability of active ingredients and their formulations (LC-UV and LC-MS).

He is a Researcher of the Biochemistry group at the Department of Pharmaceutical Sciences of the University of Piemonte Orientale. He received the master degree in Pharmaceutical Chemistry and Technology at the University of Parma and then the PhD in Pharmaceutical and Food Biotechnologies at the University of Piemonte Orientale. Dr. Miggiano was visiting PhD student at the Institute of Biosciences and BioResources of CNR in Naples and at Luis Serrano’s group at the Centre for Genomic Regulation in Barcellona where he get familiar with innovative biochemical assays for testing enzyme activity and for protein/protein interaction analysis. In 2018, he conducted part of his research at the City University of New York (CUNY). During the experience at CUNY he performed cryo-EM studies on protein complexes involved in DNA repair. His activity resulted in 15 published papers and 17 protein structures deposited in the Protein Data Bank. Moreover, Dr. Miggiano is a co-founder of the IXTAL spin-off (www.ixtal.it), a biotech company that operates in the field of protein science. His research activity mainly focus on i) the biochemical and structural characterization of individual enzymes involved in alkylated-DNA repair in Mycobacterium tuberculosis (Mtb); ii) the identification and characterization of macromolecular complexes participating to the maintenance of Mtb genome stability; iii) protein engineering studies for the design of self-labeling fluorescent protein-tag.

She received her Degree in Pharmaceutical Chemistry and Technology at UPO in 1999 and since 2001 she has worked as chemistry laboratory technician at the Department of Pharmaceutical Sciences (UPO). She tutors many different laboratories for students, ranging from analytics to pharmaceutical technology.

She received her degree in Pharmaceutical Chemistry and Technology at the University of Turin in 1998. Currently, she is Assistant Professor of Pharmaceutical Technology at the Department of Pharmaceutical Sciences (UPO). Her research interests focus on the preformulation of pharmaceutical and cosmetic molecules by interaction with excipients/technological adjuvants, formation of supra-molecular inclusion compounds with cyclodextrins and modification of the physical state by techniques such as freeze drying and spray drying.

He received his PhD in Science of Bioactive Compounds at UPO in 2008 and in the same year he visited the laboratory of “Pharmacology, Toxicology and Pharmacovigilance” Department at the University Hospital of Limoges (FR).  At present, he is post-Doctoral researcher and lecturer in Pharmaceutical Analysis at the Department of Pharmaceutical Sciences (UPO). His research interests focus on chemical stability and ADME properties evaluation of drugs and bioactive substances: in vitro/vivo drug metabolism, development and validation of HPLC-UV/MS analytical and bioanalytical methods for the determination of active pharmaceutical ingredients, their degradation products and metabolites.

She graduated in Medicine and Surgery in 2000, and then completed her residency in Dermatology and Venereology in 2005 at the University of Piemonte Orientale, Novara. In 2007 she obtained the II Level Surgical Dermatology Master at the University of Siena. In 2009 she received the title of PhD in Clinical and Experimental Medicine at the UPO, and started a post-doc fellowship at the Molecular Virology Lab (Prof Gariglio), UPO, with a project on the promoting role of Beta-Papillomaviruses in skin carcinogenesis.
Since 2012 she is working at the Dermatology Unit, University-Hospital Maggiore della Carità Novara. Her main fields of interest are represented by cutaneous oncology (including melanoma and Non-Melanoma Skin Cancers), and the dermatologic management of Organ Transplant Patients. She is currently involved in clinical trials on the Hedgehog-pathway inhibitors for the treatment of Basal Cell Carcinoma.

Maurizio Rinaldi obtained a PhD degree in Elementary Particles Physics at the International School for Advanced Studies in Trieste (Italy).
Afterwards he got Postdoctoral fellowships at Harvard University, Cambridge (MA), USA and a Postdoctoral fellowship at the Milan University (Italy).

He as been researcher of Mathematical Analysis (1995-1999) and subsequently from 1999 Associate Professor of Geometry and from 2004 in Complementary Mathematics.
He taught in Harvard University, Università degli studi di Trieste, and Università del Piemonte Orientale.
He worked in different areas of mathematical physics, geometry and analysis.
He also devoted his attention to the teaching of mathematics to students of not math-oriented undergraduate courses.
Currently he works as a mathematician and statistician with research groups of his University applying statistical learning techniques, bioinformatics and simulation of complex systems in different topics of research mainly in the chemical-biological area.

Dmitry Lim graduated from the Moscow State University in Physiology and obtained PhD in Physiology and Cell Biology at the Zoological Station “Anton Dohrn” in Naples and the Open University of London. Currently he is Associate Professor of Physiology at the Department of Pharmaceutical Sciences (UPO).

Patho-physiology of cellular calcium signaling has always been in the center of Dmitry Lim’s research career. His main interests include: i) Alterations of calcium-mediated signaling in neurodegeneration with focus on Alzheimer’s disease; ii) Patho-physiology and modelling of astroglial cells; iii) Role of calcium signaling in inter-organellar communication. Current research projects include: i) Generation and characterization of cellular models of rare diseases for drug development and repurposing; ii) Modulation of the endoplasmic reticulum-mitochondria interaction by neuroactive steroids in chemotherapy-induced peripheral neuropathy; iii) Development of chemo-genetic approach for detection and modulation of inter-organellar contact sites.

Claudio Jommi is Professor of Management at the Department of Pharmaceutical Sciences, and Director of Master of Regulatory Sciences and Market Access for Medicines and Biotechnologies (DRMKA), Università del Piemonte Orientale, Novara, Italy. He is also member of the Patent and Spin Off Committee of the same University. He was Professor of Practice of Health Policy at SDA Bocconi School of Management, where he held the position of Director of the Master of International Health Care Management Economics and Policy (Mihmep), and Director of the Health Policy Area and Scientific Coordinator of the Pharmaceutical Observatory at Cergas (Centre for Research on Health and Social Care Management). He was the President of the Italian Health Economics Association. He is the Editor in Chief of GRHTA (Global and Regional Health Technology Assessment). His research activity is focused on Pharmaceutical Economics, Policy and Management, Health Technology Assessment, Innovation management. He has had his work published in many international and national journals, including Applied Health Economics and Policy, BMC Health Services Research, BMJ Open, Drug Design Development and Therapy, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics and Pharmacoeconomics Open, PLOS and PLOS Neglected Diseases, Public Money and Management, Social Science and Medicine, Value in Health.

For complete biography, see the Key Staff page

For complete biography, see the Key Staff page

Gregorio Fernández obtained his degree in Chemistry in 1987. His research work has focused mainly on the study of the conformation of soluble and membrane proteins, and their conformational changes associated after interaction with effectors or other proteins. He has specialized in the computational design of proteins, and in the development of methodologies to predict “in silico” the protein-protein interactions at the level of soluble interaction domains, being able to extend these predictions to the complete genome of specific species. These techniques have been used successfully to improve the affinity and specificity of already known ligands, or to discover new effectors to regulate protein function. He is founder of a spin-off biotechnological company (Antalgenics SL), focused on the discovery of active molecules for dermocosmetic and biomedical applications. At present, he is a Full Professor of Biochemistry and Molecular Biology, and the responsible for the Degree in Biotechnology, as Vice Dean of the Faculty of Experimental Sciences at Miguel Hernandez University.

Enrique Barrajón-Catalán obtained his degree in Biochemistry in 1999 and in Pharmacy in 2011. At present, he is professor in Pharmacy Faculty of Universidad Miguel Hernández (Spain) and participates in the Master on Biotechnology and Bioengineering, Master on Clinic Pharmacokinetics and Individual Posology and in the PhD Program on Molecular and Cellular Biology of this university. His research is focused in biological activity of natural compounds, with special interest on cosmetic, antimicrobial, antiobesity and anticancer activities. He has agreements of collaboration and contracts with companies for the evaluation of the efficacy, quality, safety and development of new bioactive compounds. He is founder of Ilice Effitech S.L. a biotechnology Spin-off recently created and focused in the new developments for cosmetics industries.

Vicente Micol (1963, Lérida, Spain) is the head of the research group “Development and Design of Bioactive Molecules” at the Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche” (IDiBE) of the Miguel Hernández University (UMH). He obtained his PhD at the University of Murcia (Spain) on biomembranes and made his postdoctoral research at the Division of Biology of CALTECH (Pasadena, CA) in mitochondrial diseases. Currently he is Full Professor of Biochemistry and Molecular Biology at the UMH. His research group is focused on the biological activity and mechanism-of-action of polyphenols and their application to alleviate human chronic diseases such as cancer, obesity and non-communicable diseases using cell and animal models and human trials. The group has also an intense activity on technology transfer and services to companies belonging to areas such as food market, functional beverages, nutraceuticals and dermocosmetics. Founding member of several spin-off and technology-based companies, two of them focused on nutraceuticals (Nutracitrus and Mitra SolTech) and another one on efficacy assays for cosmetics (Ilice Effitech).

María Herranz-Lopez obtained her degrees in Human Nutrition and Dietetics (2006) and Food Science and Technology (2008) with an extraordinary prize upon graduation. At present, she is an Associate Professor of Biochemistry and Molecular Biology Department and participates in the Master on Biotechnology and Bioengineering and in the PhD Program on Molecular and Cellular Biology of the IDiBE. She has close relationship with biotechnological companies, where she has obtained experience not only in applied research, but also in team development and supervision. She has been working in Mitra Sol. Technologies and participating in contracts and projects in others biotechnological companies such as MONTELOEDER and INVITROTECNIA for the evaluation of the efficacy, quality, safety and development of cosmetics and nutricosmetics. Recently, she is co-founder of Ilice Effitech, SL., a Spin-off company focused in R&D for cosmetics and functional ingredients.

Antonio Bolaños collects more than 25 years of professional experience in Finance, working on different financial roles. Antonio has been Chief Financial Officer and Managing Director at The Volvo Ocean Race for 9 years, which is a major international sport event based in Spain. He has been involved in the last three editions of The Volvo Ocean Race (three-year cycles); he was passionate about sport events and had a strong previous background on financial control, planning and strategy, so he could not have found a better project merging all of them.

Antonio started his career in PricewaterhouseCoopers, where he was 8 years an External Auditor within TICE sector (Technology, Information, Communications and Entertainment). After that, he accumulated further experience in other financial positions in Spain and The United States.
Although if there is a professional passion that Antonio has, that is Training. During his time in PricewaterhouseCoopers he was combining his tasks in auditing and consulting projects with his role initially as Trainer and later as Responsible of Training for New Auditors. One of the basic principles that Antonio is declaring and strongly supporting is that professional experience is key on the training job; one of his slogans is that: “we have trainers and not subjects to learn from”.
Antonio is dedicating extensive time to training to become a key pillar of his current career, both on the academic and corporate learning fields. He has continuously participated during the last years in many workshops, conferences, forums, congresses and seminars and he is nowadays an MBA and University professor and Corporate Trainer and Advisor.

For complete biography, see the Key Staff page

For complete biography, see the Key Staff page

Gregorio Fernández obtained his degree in Chemistry in 1987. His research work has focused mainly on the study of the conformation of soluble and membrane proteins, and their conformational changes associated after interaction with effectors or other proteins. He has specialized in the computational design of proteins, and in the development of methodologies to predict “in silico” the protein-protein interactions at the level of soluble interaction domains, being able to extend these predictions to the complete genome of specific species. These techniques have been used successfully to improve the affinity and specificity of already known ligands, or to discover new effectors to regulate protein function. He is founder of a spin-off biotechnological company (Antalgenics SL), focused on the discovery of active molecules for dermocosmetic and biomedical applications. At present, he is a Full Professor of Biochemistry and Molecular Biology, and the responsible for the Degree in Biotechnology, as Vice Dean of the Faculty of Experimental Sciences at Miguel Hernandez University.

Enrique Barrajón-Catalán obtained his degree in Biochemistry in 1999 and in Pharmacy in 2011. At present, he is professor in Pharmacy Faculty of Universidad Miguel Hernández (Spain) and participates in the Master on Biotechnology and Bioengineering, Master on Clinic Pharmacokinetics and Individual Posology and in the PhD Program on Molecular and Cellular Biology of this university. His research is focused in biological activity of natural compounds, with special interest on cosmetic, antimicrobial, antiobesity and anticancer activities. He has agreements of collaboration and contracts with companies for the evaluation of the efficacy, quality, safety and development of new bioactive compounds. He is founder of Ilice Effitech S.L. a biotechnology Spin-off recently created and focused in the new developments for cosmetics industries.

Vicente Micol (1963, Lérida, Spain) is the head of the research group “Development and Design of Bioactive Molecules” at the Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche” (IDiBE) of the Miguel Hernández University (UMH). He obtained his PhD at the University of Murcia (Spain) on biomembranes and made his postdoctoral research at the Division of Biology of CALTECH (Pasadena, CA) in mitochondrial diseases. Currently he is Full Professor of Biochemistry and Molecular Biology at the UMH. His research group is focused on the biological activity and mechanism-of-action of polyphenols and their application to alleviate human chronic diseases. Founding member of several spin-off and technology-based companies focused on development of nutraceuticals and cosmetics (Nutracitrus, Mitra SolTech and, Ilice Effitech and Innovation Labo).

Main scientific achievements: participation/direction in 28 national/international competitive projects; Participation in 85 contracts, 38 service provisions and 7 patents or Know-how transfer license agreement; 195 indexed scientific articles (SCOPUS), 180 scientific communications to congresses, 2 National Research Awards, director of 16 PhD thesis, H-index of 55/65 (SCOPUS/ Google Academics) and 8460 citations (January 2024).

María Herranz-Lopez obtained her degrees in Human Nutrition and Dietetics (2006) and Food Science and Technology (2008) with an extraordinary prize upon graduation. At present, she is an Associate Professor of Biochemistry and Molecular Biology Department and participates in the Master on Biotechnology and Bioengineering and in the PhD Program on Molecular and Cellular Biology of the IDiBE. She has close relationship with biotechnological companies, where she has obtained experience not only in applied research, but also in team development and supervision. She has been working in Mitra Sol. Technologies and participating in contracts and projects in others biotechnological companies such as MONTELOEDER and INVITROTECNIA for the evaluation of the efficacy, quality, safety and development of cosmetics and nutricosmetics. Recently, she is co-founder of Ilice Effitech, SL., a Spin-off company focused in R&D for cosmetics and functional ingredients.

Antonio Bolaños collects more than 25 years of professional experience in Finance, working on different financial roles. Antonio has been Chief Financial Officer and Managing Director at The Volvo Ocean Race for 9 years, which is a major international sport event based in Spain. He has been involved in the last three editions of The Volvo Ocean Race (three-year cycles); he was passionate about sport events and had a strong previous background on financial control, planning and strategy, so he could not have found a better project merging all of them.

Antonio started his career in PricewaterhouseCoopers, where he was 8 years an External Auditor within TICE sector (Technology, Information, Communications and Entertainment). After that, he accumulated further experience in other financial positions in Spain and The United States.
Although if there is a professional passion that Antonio has, that is Training. During his time in PricewaterhouseCoopers he was combining his tasks in auditing and consulting projects with his role initially as Trainer and later as Responsible of Training for New Auditors. One of the basic principles that Antonio is declaring and strongly supporting is that professional experience is key on the training job; one of his slogans is that: “we have trainers and not subjects to learn from”.
Antonio is dedicating extensive time to training to become a key pillar of his current career, both on the academic and corporate learning fields. He has continuously participated during the last years in many workshops, conferences, forums, congresses and seminars and he is nowadays an MBA and University professor and Corporate Trainer and Advisor.

For complete biography, see the Key Staff page

Laurent Ravez has a master in philosophy and a PhD in bioethics. Since 2005, he has been head of the Center of Bioethics of the University of Namur. Professor at the University of Namur, he also teaches research ethics and ethics of public health at the Saint Joseph University of Beirut and University of Mahajanga (Madagascar). After a 12 years grant with Fogarty International (NIH) “Strengthening capacities in bioethics and justice in health”, he is now focused on publishing the research outputs.

After being graduated in pharmaceutical sciences in 2011, Dr. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015. In 2018, he gained an academic position at the University. The researches directed by Dr. Douxfils play a leading role in the establishment of guidelines for the laboratory measurement of DOACs in the routine setting. These recommendations have been used so far by several Expert Societies involved in the field of thrombosis and hemostasis. He also exercises his expertise as a pharmacovigilance expert at the European Medicine Agency, is co-chairmen of the SSC Control of Anticoagulation at the International Society of Thrombosis and Haemostasis (ISTH) and is also the co-founder and the CEO of QUALIblood, a Contract Research Organization (CRO) aiming to provide the industries, hospitals and universities with all the analytical services for blood investigations and hemocompatibility testing.

Passionate about clinical and laboratory research, he is involved in several projects aiming to solve pharmacological and/or epidemiological problems especially in thrombosis and hemostasis. Thanks to his translational view, i.e. from basic research to post-marketing pharmacovigilance, of the pharmaceutical and biomedical market, his collaborations with key opinion leaders but also with field practitioners, Dr. Jonathan Douxfils puts its expertise and know-how at the services of projects aiming to improve the safety and effectiveness of therapeutic agents in order to promote public health.

Isabelle Brenes is currently Project Manager at Bristol-Myers Squibb via Syneos Health and a visiting lecturer at UNamur. After obtaining a Master in Chemistry, she started her career working as an academic researcher in the field of inflammatory disease. Following this experience, she moved to the clinical research industry and has endorsed various roles within clinical operations in Belgium. Working on a broad diversity of therapeutic domains, for various sponsors and CROs, she has more than 12 years of experience in managing trials and supporting clinical sites and pharmaceutical companies to conduct clinical studies in compliance with Good Clinical Practice and local regulation. On top of her clinical trial expertise, Isabelle is also very interested in developing new Business opportunities and has recently obtained a Master in Executive Management at Solvay Brussels School.

After a PhD in Molecular Biology, she worked in private companies in the field of drug development, in different roles covering all aspects of quality assurance and regulatory requirements. As director of operations in accredited labs, she has lead the development and validation of analytical methods used in ISO17025/CLIA/GLP/GCLP/GMP regulatory contexts. As head of production in a CMO specialized in the production of viral vectors, she has supervised the GMP compliance of activities in a sterile/BL3 environment. As head of a clinical unit, she has managed the conduct of phase one clinical trials. Currently director of operations in a company in charge of the supply chain of clinical trials, she supervises the packaging and labelling of IMP, their storage and distribution, as well as the biobanking of human samples.

Pr. Charlotte Beaudart is a full-time lecturer in the Department of Biomedical Sciences at the Faculty of Medicine, and is a member of the NARILIS Institute. She is responsible in particular for the Master degree in Biomedical Sciences specialised in clinical research. 
Dr. Charlotte Beaudart obtained her PhD in Public Health, Epidemiology and Health Economics in the University of Liège, Belgium in 2016. Over the past 11 years, her primary focus has revolved around the intricate aspects of aging, delving into areas such as sarcopenia, frailty, and intrinsic capacities. With over 170 scientific publications to her name and an H-index of 40, Charlotte Beaudart has made a name for herself in the field of research into ageing. Beyond those research acumen, Dr. Beaudart has cultivated expertise in various methodological domains including the realm of meta-synthesis, encompassing systematic reviews, network meta-analysis and individual participant data meta-analysis. Her mastery extends to Patient Reported Outcome Measures, where she focuses on the development, validation, and statistical analysis of psychometric properties.
Furthermore, Dr. Beaudart’s academic journey includes a 3-year postdoctoral stay at the Department of Health Services Research at Maastricht University. This experience has equipped her with expertise in patient preference studies and cost-effectiveness analyses.
Dr. Beaudart is also a member of the WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, housed within the Division of Public Health, Epidemiology, and Health Economics at the University of Liège, Belgium. Furthermore, she serves as a board member of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Disease (ESCEO).

For complete biography, see the Key Staff page

Laurent Ravez has a master in philosophy and a PhD in bioethics. Since 2005, he has been head of the Center of Bioethics of the University of Namur. Professor at the University of Namur, he also teaches research ethics and ethics of public health at the Saint Joseph University of Beirut and University of Mahajanga (Madagascar). After a 12 years grant with Fogarty International (NIH) “Strengthening capacities in bioethics and justice in health”, he is now focused on publishing the research outputs.

After being graduated in pharmaceutical sciences in 2011, Dr. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015. In 2018, he gained an academic position at the University. The researches directed by Dr. Douxfils play a leading role in the establishment of guidelines for the laboratory measurement of DOACs in the routine setting. These recommendations have been used so far by several Expert Societies involved in the field of thrombosis and hemostasis. He also exercises his expertise as a pharmacovigilance expert at the European Medicine Agency, is co-chairmen of the SSC Control of Anticoagulation at the International Society of Thrombosis and Haemostasis (ISTH) and is also the co-founder and the CEO of QUALIblood, a Contract Research Organization (CRO) aiming to provide the industries, hospitals and universities with all the analytical services for blood investigations and hemocompatibility testing.

Passionate about clinical and laboratory research, he is involved in several projects aiming to solve pharmacological and/or epidemiological problems especially in thrombosis and hemostasis. Thanks to his translational view, i.e. from basic research to post-marketing pharmacovigilance, of the pharmaceutical and biomedical market, his collaborations with key opinion leaders but also with field practitioners, Dr. Jonathan Douxfils puts its expertise and know-how at the services of projects aiming to improve the safety and effectiveness of therapeutic agents in order to promote public health.

Isabelle Brenes is currently Project Manager at Bristol-Myers Squibb via Syneos Health and a visiting lecturer at UNamur. After obtaining a Master in Chemistry, she started her career working as an academic researcher in the field of inflammatory disease. Following this experience, she moved to the clinical research industry and has endorsed various roles within clinical operations in Belgium. Working on a broad diversity of therapeutic domains, for various sponsors and CROs, she has more than 12 years of experience in managing trials and supporting clinical sites and pharmaceutical companies to conduct clinical studies in compliance with Good Clinical Practice and local regulation. On top of her clinical trial expertise, Isabelle is also very interested in developing new Business opportunities and has recently obtained a Master in Executive Management at Solvay Brussels School.

After a PhD in Molecular Biology, she worked in private companies in the field of drug development, in different roles covering all aspects of quality assurance and regulatory requirements. As director of operations in accredited labs, she has lead the development and validation of analytical methods used in ISO17025/CLIA/GLP/GCLP/GMP regulatory contexts. As head of production in a CMO specialized in the production of viral vectors, she has supervised the GMP compliance of activities in a sterile/BL3 environment. As head of a clinical unit, she has managed the conduct of phase one clinical trials. Currently director of operations in a company in charge of the supply chain of clinical trials, she supervises the packaging and labelling of IMP, their storage and distribution, as well as the biobanking of human samples.

Pr. Charlotte Beaudart is a full-time lecturer in the Department of Biomedical Sciences at the Faculty of Medicine, and is a member of the NARILIS Institute. She is responsible in particular for the Master degree in Biomedical Sciences specialised in clinical research. 
Dr. Charlotte Beaudart obtained her PhD in Public Health, Epidemiology and Health Economics in the University of Liège, Belgium in 2016. Over the past 11 years, her primary focus has revolved around the intricate aspects of aging, delving into areas such as sarcopenia, frailty, and intrinsic capacities. With over 170 scientific publications to her name and an H-index of 40, Charlotte Beaudart has made a name for herself in the field of research into ageing. Beyond those research acumen, Dr. Beaudart has cultivated expertise in various methodological domains including the realm of meta-synthesis, encompassing systematic reviews, network meta-analysis and individual participant data meta-analysis. Her mastery extends to Patient Reported Outcome Measures, where she focuses on the development, validation, and statistical analysis of psychometric properties.
Furthermore, Dr. Beaudart’s academic journey includes a 3-year postdoctoral stay at the Department of Health Services Research at Maastricht University. This experience has equipped her with expertise in patient preference studies and cost-effectiveness analyses.
Dr. Beaudart is also a member of the WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, housed within the Division of Public Health, Epidemiology, and Health Economics at the University of Liège, Belgium. Furthermore, she serves as a board member of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Disease (ESCEO).